aHUS Trial Watch 18 – subcutaneous Ravulizumab
To the best of Global Action’s knowledge there has not been a trial of subcutaneous Ravulizumab for use in the treatment…
Personalised Treatment Delivery – aHUS Agenda Topic 4
aHUS patients are likely to have personal preferences for a treatment and as more options become available a personalised approach for…
Meningococcal Infection – Symptoms
Complement Inhibitor users are the group at most risk of meningococcal infection according to the Centre for Disease Control in the…
Diagnosis – aHUS Agenda Topic 3
An accurate and rapid aHUS Diagnosis is essential to the best of aHUS patients health outcome. Our expert gave a response…
Familial Genetic Testing- aHUS Agenda Topic 2-
The series about the aHUS Research Agenda continues with second topic about familial genetic testing. When it comes to genetic testing…
Cause Factors- aHUS Agenda Topic 1
"What the heck hit me to cause that and why" are not an unreasonable question for aHUS patients to ask. Collectively…
Is an aHUS patient research agenda worthwhile?
aHUS patients have a global research agenda. Work began on it in 2015 and after three iterations involving more than 200…
Could there be a LONG aHUS like LONG COVID?
We asked an expert “ Have you heard about Long COVID? Given the similarities could there be a LONG aHUS?” This…
KDIGO and aHUS treatment guidelines
KDIGO stands for Kidney Disease: Improving Global Outcomes. It is a global nonprofit organization that develops and publishes clinical practice guidelines…
- Go to the previous page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- …
- 24
- Go to the next page